Friday, April 18, 2014

Enter to Win a Free ErgoSure™ Stool with DentalEZ® Group’s “#MYERGOSURE” Facebook Sweepstakes

-->

Malvern, PA (April 14, 2014) – DentalEZ® Group, a supplier of innovative products and services for dental health professionals worldwide, is pleased to announce its #MYERGOSURE Sweepstakes. Currently running on the DentalEZ Group Facebook page, the sweepstakes provides all participants a chance to win a free ErgoSure operator or assistant stool.

Open to all practicing licensed dentists, hygienists and dental assistants, the #MYERGOSURE sweepstakes runs from April 3, 2014 through June 30, 2014. Entering the sweepstakes is easy. DentalEZ Group Facebook fans can simply visit the DentalEZ Facebook page at facebook.com/dentalezgroup and click on the “#MYERGOSURE SWEEPSTAKES” tab. An online registration entry form will appear and dental professionals will be prompted to complete the form as instructed.  

Non-fans of the DentalEZ Facebook page can also enter for a chance to win. All dental professionals who are not currently fans of the page are invited to visit the DentalEZ Facebook page and will be eligible to enter the sweepstakes simply by choosing to “like” the page. Once the page is liked, the online registration entry form will appear and the dental professional will be prompted to enter their contact information to be entered in the sweepstakes.

#MYERGOSURE Sweepstakes participants can submit up to one entry per day, and each submission counts as one entry for the grand prize. The grand prize winner will be selected and notified in a random drawing on or about July 14, 2014.  
The design of all ErgoSure Stools centers on the long-standing DentalEZ philosophy of offering ergonomic design and functionality. All ErgoSure Stools are equipped with 4 independent seat mechanisms for easy adjustment of height, seat tilt, back in and out, and concealed height-adjustable lumbar support. All adjustable features enable the dental professional to easily position the stools while seated using one hand.

All ErgoSure stools are equipped with an integral non-slip skin foam technology texture that is fluid-proof and easy to disinfect. ErgoSure operator stools include a built-in adapter for easy attachment of Free-Motion Elbow Supports, which effectively support the elbow during procedures but do not interfere with the movement of the dental professional.

To enter the #MYERGOSURE Sweepstakes, please visit facebook.com/dentalezgroup.

Please visit DentalEZ Group’s ErgoSure stool product page for more information on the complete line of ErgoSure stools.  

About DentalEZ® Group

DentalEZ® Group is committed to advancing the practice of dentistry through innovative products and services. Encompassing six distinct product brands — StarDental®, DentalEZ®, CustomAir®, RAMVAC®, NevinLabs and Columbia Dentoform® — DentalEZ® Group manufactures everything in the operatory, from handpieces to chairs to vacuum systems to dental simulation models, creating a complete line of products to elevate the health, comfort
and efficiency of the dental operatory. For more information, please visit
dentalez.com.

# # #

Wednesday, April 16, 2014

Night time only braces?



An Israeli company gives orthodontics new bite! An Israeli company has developed a teeth-straightening device that frees patients from having to wear aligners or unsightly braces. The device, which they say is as effective as conventional straighteners, utilities an air-driven pulsating plate and is designed to be worn only at night.

Tuesday, April 15, 2014

The effect of oral appliances that advanced the mandible forward and limited mouth opening in patients with obstructive sleep apnea: A systematic review and meta-analysis of randomised controlled trials

Cover image for Vol. 41 Issue 4
Journal of Oral Rehabilitation
Early View (Online Version of Record published before inclusion in an issue

 

Summary

Oral appliances (OAs) have demonstrated efficacy in treating obstructive sleep apnea (OSA), but many different OA devices are available. The Japanese Academy of Dental Sleep Medicine supported the use of OAs that advanced the mandible forward and limited mouth opening and suggested an evaluation of their effects in comparison with untreated or CPAP. A systematic search was undertaken in 16 April 2012. The outcome measures of interest were as follows: Apnea Hypopnea Index (AHI), lowest SpO2, arousal index, Epworth Sleepiness Scale (ESS), the SF-36 Health Survey. We performed this meta-analysis using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Five studies remained eligible after applying the exclusion criteria. Comparing OA and control appliance, OA significantly reduced the weighted mean difference (WMD) in both AHI and the arousal index (favouring OA, AHI: −7·05 events h−1; 95% CI, −12·07 to −2·03; P = 0·006, arousal index: −6·95 events h−1; 95% CI, −11·75 to −2·15; P = 0·005). OAs were significantly less effective at reducing the WMD in AHI and improving lowest SpO2 and SF-36 than CPAP, (favouring OA, AHI: 6·11 events h−1; 95% CI, 3·24 to 8·98; P = 0·0001, lowest SpO2: −2·52%; 95% CI, −4·81 to −0·23; P = 0·03, SF-36: −1·80; 95% CI, −3·17 to −042; P = 0·01). Apnea Hypopnea Index and arousal index were significantly improved by OA relative to the untreated disease. Apnea Hypopnea Index, lowest SpO2 and SF-36 were significantly better with CPAP than with OA. The results of this study suggested that OAs improve OSA compared with untreated. CPAP appears to be more effective in improving OSA than OAs.

Monday, April 14, 2014

Rutgers Study Finds Increased Usage of NJ Emergency Rooms for Dental Care


The Rutgers Center for State Health Policy recently released a report showing an increased usage of state emergency rooms for non-trauma related dental care visits. The report finds, among other things, that our urban areas see an increased utilization and that young-adults and African-Americans are among the highest users. Click here to view the report. To read an additional related article, click here.

Friday, April 11, 2014

Anti-Streptococcal activity of Brazilian Amazon Rain Forest plant extracts presents potential for preventive strategies against dental caries

Journal of Applied Oral Science
Print version ISSN 1678-7757
J. Appl. Oral Sci. vol.22 no.2 Bauru Mar./Apr. 2014
http://dx.doi.org/10.1590/1678-775720130366 

Caries is a global public health problem, whose control requires the introduction of low-cost treatments, such as strong prevention strategies, minimally invasive techniques and chemical prevention agents. Nature plays an important role as a source of new antibacterial substances that can be used in the prevention of caries, and Brazil is the richest country in terms of biodiversity.

Objective:
In this study, the disk diffusion method (DDM) was used to screen over 2,000 Brazilian Amazon plant extracts against Streptococcus mutans.

Material and Methods:
Seventeen active plant extracts were identified and fractionated. Extracts and their fractions, obtained by liquid-liquid partition, were tested in the DDM assay and in the microdilution broth assay (MBA) to determine their minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs). The extracts were also subjected to antioxidant analysis by thin layer chromatography.

Results:
EB271, obtained from Casearia spruceana, showed significant activity against the bacterium in the DDM assay (20.67±0.52 mm), as did EB1129, obtained from Psychotria sp. (Rubiaceae) (15.04±2.29 mm). EB1493, obtained from Ipomoea alba, was the only extract to show strong activity against Streptococcus mutans (0.08 mg/mL

Conclusions:
The active extracts, discovered in the Amazon rain forest, show potential as sources of new antibacterial agents for use as chemical coadjuvants in prevention strategies to treat caries.

Thursday, April 10, 2014

Histological changes within dental pulps in teeth with moderate to severe chronic periodontitis

Cover image for Vol. 47 Issue 4

Abstract

Aim

To investigate the effect of chronic periodontitis on dental pulps by assessing histological changes in the pulps of teeth with moderate to severe periodontitis.

Methodology

A total of 242 teeth from 162 patients with moderate to severe periodontitis were collected, and histological changes in pulps were investigated by staining with haematoxylin and eosin. Baseline data were taken from the patients’ records before extraction. The morphologic changes observed in the pulp were classified as degreeI, degree II, degree III, degree IV. Statistical analysis of the severity of periodontitis and histological changes with the pulps was applied to Mann–Whitney U rank sum test, while the contingency coefficient was used to analyze the interrelationship between the severity of periodontitis and histological changes in the pulps.

Results

The interrelationship between the severity of periodontitis and histological changes in the pulps was 0.274 (P<0 .001="" and="" between="" differences="" em="" existed="" group="" moderate="" periodontitis="" severe="" significant="" teeth="" with="">P
<0 .001="" 0.397="" and="" attachment="" between="" changes="" em="" histological="" in="" interrelationship="" loss="" pulps="" the="" was="">P<0 .001="" amongst="" attachment="" changes="" degrees="" differences="" histological="" in="" loss="" of="" significant="" sup="" teeth="" the="" there="" various="" were="" with="">2=33.023, P<0 .001="" amongst="" and="" different="" in="" locations="" sup="" teeth="">2 =23.163, P<0 .001="" p="">

Conclusions

There was a positive association between the severity of periodontitis and histological changes within the pulp. More attachment loss was correlated with pathological changes within the dental pulp.

Wednesday, April 09, 2014

Coming Soon: PeriRx LLC’s Breakthrough Salivary Test to Aid in the Fight Against Oral Cancer

-->

The World’s Most Clinically Advanced and Scientifically Validated Molecular DNA Biomarker Test for Oral Squamous Cell Carcinoma is Launching in Late Spring


Havertown, PA – April 3, 2014 – PeriRx LLC, a premier developer of breakthrough, non-invasive, oral diagnostic technology recently announced that it will be introducing the world’s most clinically advanced and scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma detection in the late spring.

According to PeriRx LLC’s CEO Stephen M. Swanick, “This is a simple-to-use, painless and noninvasive test designed for front line healthcare practitioners that enables them to detect disease earlier, enhance patient wellness and reduce the overall cost of healthcare.” 
.
The salivary test is based on a strong scientific foundation of NIH-funded research with initial discovery and pre-validation work by Dr. David Wong of the University of California at Los Angeles. The test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer.

These discriminatory salivary biomarkers have been clinically validated in multiple large trials including studies in collaboration with the National Cancer Institute and with premiere US academic medical centers such as the University of Michigan, Michigan State University and the Providence Health System in Detroit.

For more information, visit www.PeriRx.com. To become an early adopter of the salivary test, or to become an investor in PeriRx LLC, contact Stephen M. Swanick at 610-449-9625 or perirx@rcn.com.

About PeriRx LLC:

Based in Havertown, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, non-invasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.  
The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.

PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through FDA approval, and into commercialization.

# # #